Novartis AG (NYSE:NVS)

84.90
Delayed Data
As of Sep 19
 -0.13 / -0.15%
Today’s Change
72.30
Today|||52-Week Range
94.19
+1.12%
Year-to-Date
Is Now a Good Time to Buy Tilray Inc.?
Sep 18 / MotleyFool.com - Paid Partner Content
Shire's ADHD Portfolio Remains Strong Amid Competition
Sep 10 / Zacks.com - Paid Partner Content
Aduro's Cancer Arm & Strong Collaborations Boost Growth
Sep 18 / Zacks.com - Paid Partner Content
Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD
Sep 10 / Zacks.com - Paid Partner Content
Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy?
Sep 18 / MotleyFool.com - Paid Partner Content
Exelixis' Cabometyx Recommended by NCCN for All Types of RCC
Sep 10 / Zacks.com - Paid Partner Content
Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval
Sep 17 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson &...
Sep 10 / Zacks.com - Paid Partner Content
Is Artificial Intelligence the Next Big Thing in Biotech?
Sep 17 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
Sep 07 / Zacks.com - Paid Partner Content
Better Buy: Gilead Sciences, Inc. vs. Biogen
Sep 13 / MotleyFool.com - Paid Partner Content
Roche's Tecentriq sBLA Review For NSCLC Gets Extended by FDA
Sep 07 / Zacks.com - Paid Partner Content
KemPharm Posts Positive Top-Line Results on KP415 Prodrug
Sep 12 / Zacks.com - Paid Partner Content
Lilly, Teva, Pfizer & Others Await FDA Decisions in September
Sep 07 / Zacks.com - Paid Partner Content
Incyte, Foundation Medicine Partner for Companion Diagnostics
Sep 12 / Zacks.com - Paid Partner Content
Novartis to Sell Sandoz's Dermatology Business to Aurobindo
Sep 06 / Zacks.com - Paid Partner Content